2026-10-02T00:20:09.000Z · 2 days ago Cathie Wood’s ARK Investment buys 159K shares of Veracyte today
2026-09-29T12:37:38.000Z · 4 days ago Veracyte announces new findings from Phase III NRG/RTOG 0815 trial
Sep 29, 2026, 8:00 AM EDT · 4 days ago Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Sep 25, 2026, 5:12 PM EDT · 8 days ago Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
2026-09-14T20:10:29.000Z · 19 days ago Veracyte acquires Convergent Genomics for $150M in cash upfront
Sep 14, 2026, 4:05 PM EDT · 19 days ago Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Sep 1, 2026, 4:05 PM EDT · 4 weeks ago Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-28T00:20:09.000Z · 5 weeks ago Cathie Wood’s ARK Investment buys 47.8K shares of Veracyte today
2026-08-04T12:05:36.000Z · 2 months ago Veracyte price target lowered to $44 from $47 at Morgan Stanley
2026-08-04T10:56:02.000Z · 2 months ago Veracyte price target lowered to $54 from $66 at Piper Sandler
2026-07-30T20:38:26.000Z · 2 months ago Veracyte raises FY26 revenue view to $590M-$596M from $582M-$592M
Jul 9, 2026, 4:05 PM EDT · 2 months ago Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
2026-07-09T11:00:14.000Z · 2 months ago Veracyte price target raised to $47 from $37 at Morgan Stanley
Jun 1, 2026, 7:30 AM EDT · 4 months ago Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
May 30, 2026, 8:00 AM EDT · 4 months ago ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
May 29, 2026, 3:15 PM EDT · 4 months ago Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
May 27, 2026, 7:22 AM EDT · 4 months ago Veracyte genomic test identifies breast cancer patients who can skip chemo
May 22, 2026, 8:00 AM EDT · 4 months ago Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
May 21, 2026, 6:00 PM EDT · 4 months ago OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
May 15, 2026, 9:00 AM EDT · 4 months ago Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Apr 28, 2026, 9:00 AM EDT · 5 months ago Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
Apr 14, 2026, 4:05 PM EDT · 5 months ago Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
Mar 16, 2026, 4:15 PM EDT · 6 months ago Veracyte Names Kevin Haas as Chief Development and Technology Officer
Feb 25, 2026, 4:05 PM EST · 7 months ago Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
Feb 24, 2026, 9:00 AM EST · 7 months ago Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
Feb 4, 2026, 5:15 PM EST · 8 months ago Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Jan 11, 2026, 4:30 PM EST · 8 months ago Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Dec 29, 2025, 4:30 PM EST · 9 months ago Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Nov 3, 2025, 4:15 PM EST · 11 months ago Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
Oct 15, 2025, 5:31 PM EDT · 11 months ago Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
Sep 28, 2025, 4:00 PM EDT · 1 year ago Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
Sep 24, 2025, 9:00 AM EDT · 1 year ago Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
Sep 9, 2025, 9:00 AM EDT · 1 year ago Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
Aug 29, 2025, 8:30 AM EDT · 1 year ago Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 27, 2025, 11:25 AM EDT · 1 year ago Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Aug 26, 2025, 8:30 AM EDT · 1 year ago Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
Jul 17, 2025, 5:30 PM EDT · 1 year ago Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
Jul 8, 2025, 4:05 PM EDT · 1 year ago Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
May 28, 2025, 4:05 PM EDT · 1 year ago Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
Apr 25, 2025, 7:00 AM EDT · 1 year ago Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
Apr 22, 2025, 9:00 AM EDT · 1 year ago Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
Apr 21, 2025, 4:05 PM EDT · 1 year ago Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release
Mar 25, 2025, 4:05 PM EDT · 1 year ago New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
Mar 19, 2025, 5:00 PM EDT · 1 year ago Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
Feb 24, 2025, 4:05 PM EST · 1 year ago Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
Feb 14, 2025, 8:30 AM EST · 1 year ago New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
Feb 11, 2025, 8:30 AM EST · 1 year ago Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
Feb 5, 2025, 8:30 AM EST · 1 year ago New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
Feb 4, 2025, 4:30 PM EST · 1 year ago Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
Dec 5, 2024, 4:05 PM EST · 1 year ago Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
Oct 16, 2024, 6:43 PM EDT · 1 year ago Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024